ReviewVirchows Archiv : an international journal of pathology2015
The immune response in cancer: from immunology to pathology to immunotherapy.
Review in Virchows Archiv : an international journal of pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical Significance of Pre-treated Neutrophil-Lymphocyte Ratio in the Management of Urothelial Carcinoma: A Systemic Review and Meta-Analysis.Frontiers in oncology · 2019Pooled it
- T cells responding to Trypanosoma cruzi detected by membrane TNF-α and CD154 in chagasic patients.Immunity, inflammation and disease · 2018Trial
- Article
- Messenger RNA ofSovremennye tekhnologii v meditsine · 2022Article
- Regulation of Immune Cells by microRNAs and microRNA-Based Cancer Immunotherapy.Advances in experimental medicine and biology · 2022Article
- Epigenetic quantification of circulating immune cells in peripheral blood of triple-negative breast cancer patients.Clinical epigenetics · 2021Article
- Modulating the Heat Stress Response to Improve Hyperthermia-Based Anticancer Treatments.Cancers · 2021Review
- Article
- Clinical Significance of Glucose to Lymphocyte Ratio (GLR) as a Prognostic Marker for Patients With Pancreatic Cancer.Frontiers in oncology · 2020Article
- CD163+ immune cell infiltrates and presence of CD54+ microvessels are prognostic markers for patients with embryonal rhabdomyosarcoma.Scientific reports · 2019Article
- Tertiary lymphoid structures in the era of cancer immunotherapy.Nature reviews. Cancer · 2019Review
- Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology.Virchows Archiv : an international journal of pathology · 2019Review
- Neutrophil to Lymphocyte Ratio is a Predictive Factor of Malignant Potential for Intraductal Papillary Mucinous Neoplasms of the pancreas.Biomarker insights · 2019Article
- The clinical role of the TME in solid cancer.British journal of cancer · 2019Review
- Evaluation of neutrophil-to-lymphocyte ratio and calcitonin concentration for predicting lymph node metastasis and distant metastasis in patients with medullary thyroid cancer.Molecular and clinical oncology · 2018Article
- Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients.PloS one · 2018Article
- Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy.Cancer management and research · 2018Article
- Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.The oncologist · 2017Article
- White blood cell and platelet indices as prognostic markers in patients with invasive ductal breast carcinoma.Oncology letters · 2016Article
- Impact of CDT Toxin on Human Diseases.Toxins · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the recent years, breakthrough advances in the characterization of the tumor-infiltrating immune cells and in the understanding of their influence on tumor invasion and metastasis have been accomplished. These studies have allowed the development of assays quantifying immune infiltrates to predict patient's clinical outcome. Increasing evidence supports their utility as prognostic and potentially teragnostic markers. The in-depth characterization of the tumor's immune profile and the standard histopathological criteria are becoming the optimal method of tumor classification in the era of personalized medicine. This review describes the major concepts in the anti-tumor immunity field, with particular focus on the tumor immune microenvironment and the delicate balance between inflammatory and anti-tumor immune responses, its importance as a prognostic tool, and its utility as a teragnostic marker for patients receiving new-generation immunotherapies.
Indexed as
Identifiers
26077464What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.